Navigation Links
Study Aims At The Immune System In Patients With Lou Gehrig's Disease

Carolyn Shimek takes cholesterol-decreasing medications like millions of Americans. However she does not have high cholesterol like others//. This is since she is taking part in a different clinical study found only at the Methodist Neurological Institute (NI) to view the benefits of Lipitor on the immune system in patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS).

Physicians at the Methodist NI's MDA/ALS Clinical Center diagnosed the 48-year-old Victoria, Texas resident in 2005. When she learned of this investigator-initiated research, Shimek knew she had to give it a chance.

‘I have a lot to live for - my family and friends,’ said Shimek, a wife, mother of three, and one of 12 siblings. ‘If participating in this study means it will help me or other ALS patients down the road then it's worth it.’

Dr. Ericka Simpson, co-director of Methodist's ALS Clinic, is the primary investigator who oversees this double-blind study in which patients will be randomly assigned to receive the drug or a placebo. Simpson believes the immune system plays an important role in how ALS affects patients.

‘Lipitor has been shown to regulate immune responses that may provide protection in diseases of the central nervous system. Our goal is to determine whether Lipitor has the ability to improve the course of disease progression and quality of life for our ALS patients,’ said Simpson.

Currently, the only FDA-approved drug therapy for ALS is Rilutek. The drug has been shown to modestly improve patient survival, but has no measurable affect on function or the rate of disease progression. ALS is a progressive neurodegenerative disease characterized by degeneration of the upper and lower motor neurons in the brain and spinal cord which stimulate skeletal muscle movement. As more motor neurons die, muscle weakness gets progressively worse. An estimated 30,000 people throughout the U.S. have ALS, and 8,000 new cas es are diagnosed each year.

Source: Neswise
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology: